Long-term metabolic consequences of covid-19: a retrospective cohort study on new onset diabetes mellitus, hypertension, and dyslipidemia

Background: The COVID-19 pandemic caused by SARS-CoV-2 has raised concerns about its potential impact beyond acute respiratory symptoms. Emerging evidence suggests an alarming trend of newonset metabolic disorders, including diabetes mellitus, hypertension, and dyslipidemia, following recovery from COVID-19. Understanding the underlying mechanisms and risk factors is essential for devising preventive strategies and interventions. Methods: A retrospective cohort study was conducted using electronic health records (EHRs) of adult patients diagnosed with COVID-19 between January 2020 and December 2021. Patients with pre-existing metabolic disorders were excluded. Data collected included demographic information, COVID-19 severity, inammatory markers, comorbidities, and medications used during hospitalization. Results: Among 380 patients, 26.3% developed new-onset diabetes, 39.5% experienced new-onset hypertension, and 34.2% developed new-onset dyslipidemia post-COVID-19 recovery. Age, COVID-19 severity, inammatory markers, and pre-existing comorbidities were identied as signicant risk factors associated with new-onset metabolic disorders. Conclusion: This study emphasizes the importance of understanding the complex relationship between COVID-19 and metabolic health to develop effective preventive and therapeutic strategies. Addressing underlying health conditions and inammation modulation may hold promise for mitigating long-term health implications post-COVID-19. This research contributes valuable insights to safeguard the well-being of individuals in the aftermath of the pandemic.